Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination
Identifieur interne : 006F15 ( Ncbi/Merge ); précédent : 006F14; suivant : 006F16Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination
Auteurs : Neal D. E. AlexanderSource :
- Transactions of the Royal Society of Tropical Medicine and Hygiene [ 0035-9203 ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Diéthylcarbamazine, Filaricides.
- organisation et administration : Mise en oeuvre des programmes de santé.
- Filariose lymphatique, Humains, Éradication de maladie.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Diethylcarbamazine, Filaricides.
- organization & administration : Health Plan Implementation.
- prevention & control : Elephantiasis, Filarial.
- Disease Eradication, Humans.
Abstract
Lymphatic filariasis has been targeted for elimination by 2020, and a threshold of 65% coverage of mass drug administration (MDA) has been adopted by the Global Programme to Eliminate Lymphatic Filariasis (GPELF). A recent review by Babu and Babu of 36 studies of MDA for lymphatic filariasis in India found that coverage, defined as receipt of tablets, ranged from 48.8 to 98.8%, while compliance, defined as actual ingestion of tablets, was 22% lower on average. Moreover, the denominator for these coverage figures is the eligible, rather than total, population. By contrast, the 65% threshold, in the original modelling study, refers to ingestion of tablets in the total population. This corresponds to GPELF's use of ‘epidemiological drug coverage’ as a trigger for the Transmission Assessment Surveys (TAS), which indicate whether to proceed to post-MDA surveillance. The existence of less strict definitions of ‘coverage’ should not lead to premature TAS that could impair MDA's sustainability.
Url:
DOI: 10.1093/trstmh/tru204
PubMed: 25575555
PubMed Central: 4321021
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 004651
- to stream Pmc, to step Curation: 004650
- to stream Pmc, to step Checkpoint: 001497
- to stream PubMed, to step Corpus: 001097
- to stream PubMed, to step Curation: 001097
- to stream PubMed, to step Checkpoint: 001097
Links to Exploration step
PMC:4321021Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination</title>
<author><name sortKey="Alexander, Neal D E" sort="Alexander, Neal D E" uniqKey="Alexander N" first="Neal D. E." last="Alexander">Neal D. E. Alexander</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25575555</idno>
<idno type="pmc">4321021</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321021</idno>
<idno type="RBID">PMC:4321021</idno>
<idno type="doi">10.1093/trstmh/tru204</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">004651</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004651</idno>
<idno type="wicri:Area/Pmc/Curation">004650</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">004650</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001497</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001497</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001097</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001097</idno>
<idno type="wicri:Area/PubMed/Curation">001097</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001097</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001097</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001097</idno>
<idno type="wicri:Area/Ncbi/Merge">006F15</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination</title>
<author><name sortKey="Alexander, Neal D E" sort="Alexander, Neal D E" uniqKey="Alexander N" first="Neal D. E." last="Alexander">Neal D. E. Alexander</name>
</author>
</analytic>
<series><title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title>
<idno type="ISSN">0035-9203</idno>
<idno type="eISSN">1878-3503</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Diethylcarbamazine (administration & dosage)</term>
<term>Disease Eradication</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Filaricides (administration & dosage)</term>
<term>Health Plan Implementation (organization & administration)</term>
<term>Humans</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Diéthylcarbamazine (administration et posologie)</term>
<term>Filaricides (administration et posologie)</term>
<term>Filariose lymphatique ()</term>
<term>Humains</term>
<term>Mise en oeuvre des programmes de santé (organisation et administration)</term>
<term>Éradication de maladie</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diethylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diéthylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Mise en oeuvre des programmes de santé</term>
</keywords>
<keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Health Plan Implementation</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Disease Eradication</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Filariose lymphatique</term>
<term>Humains</term>
<term>Éradication de maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Lymphatic filariasis has been targeted for elimination by 2020, and a threshold of 65% coverage of mass drug administration (MDA) has been adopted by the Global Programme to Eliminate Lymphatic Filariasis (GPELF). A recent review by Babu and Babu of 36 studies of MDA for lymphatic filariasis in India found that coverage, defined as receipt of tablets, ranged from 48.8 to 98.8%, while compliance, defined as actual ingestion of tablets, was 22% lower on average. Moreover, the denominator for these coverage figures is the eligible, rather than total, population. By contrast, the 65% threshold, in the original modelling study, refers to ingestion of tablets in the total population. This corresponds to GPELF's use of ‘epidemiological drug coverage’ as a trigger for the Transmission Assessment Surveys (TAS), which indicate whether to proceed to post-MDA surveillance. The existence of less strict definitions of ‘coverage’ should not lead to premature TAS that could impair MDA's sustainability.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Stolk, Wa" uniqKey="Stolk W">WA Stolk</name>
</author>
<author><name sortKey="Swaminathan, S" uniqKey="Swaminathan S">S Swaminathan</name>
</author>
<author><name sortKey="Van Oortmarssen, Gj" uniqKey="Van Oortmarssen G">GJ van Oortmarssen</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Babu, Bv" uniqKey="Babu B">BV Babu</name>
</author>
<author><name sortKey="Babu, Gr" uniqKey="Babu G">GR Babu</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Krentel, A" uniqKey="Krentel A">A Krentel</name>
</author>
<author><name sortKey="Fischer, Pu" uniqKey="Fischer P">PU Fischer</name>
</author>
<author><name sortKey="Weil, Gj" uniqKey="Weil G">GJ Weil</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Al Awadi, Ar" uniqKey="Al Awadi A">AR Al-Awadi</name>
</author>
<author><name sortKey="Al Kuhlani, A" uniqKey="Al Kuhlani A">A Al-Kuhlani</name>
</author>
<author><name sortKey="Breman, Jg" uniqKey="Breman J">JG Breman</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Richards, Fo" uniqKey="Richards F">FO Richards</name>
</author>
<author><name sortKey="Eigege, A" uniqKey="Eigege A">A Eigege</name>
</author>
<author><name sortKey="Miri, Es" uniqKey="Miri E">ES Miri</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Swaminathan, S" uniqKey="Swaminathan S">S Swaminathan</name>
</author>
<author><name sortKey="Perumal, V" uniqKey="Perumal V">V Perumal</name>
</author>
<author><name sortKey="Adinarayanan, S" uniqKey="Adinarayanan S">S Adinarayanan</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<double pmid="25575555"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination</title>
<author><name sortKey="Alexander, Neal D E" sort="Alexander, Neal D E" uniqKey="Alexander N" first="Neal D. E." last="Alexander">Neal D. E. Alexander</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25575555</idno>
<idno type="pmc">4321021</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321021</idno>
<idno type="RBID">PMC:4321021</idno>
<idno type="doi">10.1093/trstmh/tru204</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">004651</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004651</idno>
<idno type="wicri:Area/Pmc/Curation">004650</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">004650</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001497</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001497</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination</title>
<author><name sortKey="Alexander, Neal D E" sort="Alexander, Neal D E" uniqKey="Alexander N" first="Neal D. E." last="Alexander">Neal D. E. Alexander</name>
</author>
</analytic>
<series><title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title>
<idno type="ISSN">0035-9203</idno>
<idno type="eISSN">1878-3503</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Lymphatic filariasis has been targeted for elimination by 2020, and a threshold of 65% coverage of mass drug administration (MDA) has been adopted by the Global Programme to Eliminate Lymphatic Filariasis (GPELF). A recent review by Babu and Babu of 36 studies of MDA for lymphatic filariasis in India found that coverage, defined as receipt of tablets, ranged from 48.8 to 98.8%, while compliance, defined as actual ingestion of tablets, was 22% lower on average. Moreover, the denominator for these coverage figures is the eligible, rather than total, population. By contrast, the 65% threshold, in the original modelling study, refers to ingestion of tablets in the total population. This corresponds to GPELF's use of ‘epidemiological drug coverage’ as a trigger for the Transmission Assessment Surveys (TAS), which indicate whether to proceed to post-MDA surveillance. The existence of less strict definitions of ‘coverage’ should not lead to premature TAS that could impair MDA's sustainability.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Stolk, Wa" uniqKey="Stolk W">WA Stolk</name>
</author>
<author><name sortKey="Swaminathan, S" uniqKey="Swaminathan S">S Swaminathan</name>
</author>
<author><name sortKey="Van Oortmarssen, Gj" uniqKey="Van Oortmarssen G">GJ van Oortmarssen</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Babu, Bv" uniqKey="Babu B">BV Babu</name>
</author>
<author><name sortKey="Babu, Gr" uniqKey="Babu G">GR Babu</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct><analytic><author><name sortKey="Krentel, A" uniqKey="Krentel A">A Krentel</name>
</author>
<author><name sortKey="Fischer, Pu" uniqKey="Fischer P">PU Fischer</name>
</author>
<author><name sortKey="Weil, Gj" uniqKey="Weil G">GJ Weil</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Al Awadi, Ar" uniqKey="Al Awadi A">AR Al-Awadi</name>
</author>
<author><name sortKey="Al Kuhlani, A" uniqKey="Al Kuhlani A">A Al-Kuhlani</name>
</author>
<author><name sortKey="Breman, Jg" uniqKey="Breman J">JG Breman</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Richards, Fo" uniqKey="Richards F">FO Richards</name>
</author>
<author><name sortKey="Eigege, A" uniqKey="Eigege A">A Eigege</name>
</author>
<author><name sortKey="Miri, Es" uniqKey="Miri E">ES Miri</name>
</author>
</analytic>
</biblStruct>
<biblStruct><analytic><author><name sortKey="Swaminathan, S" uniqKey="Swaminathan S">S Swaminathan</name>
</author>
<author><name sortKey="Perumal, V" uniqKey="Perumal V">V Perumal</name>
</author>
<author><name sortKey="Adinarayanan, S" uniqKey="Adinarayanan S">S Adinarayanan</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
</pmc>
<pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination.</title>
<author><name sortKey="Alexander, Neal D E" sort="Alexander, Neal D E" uniqKey="Alexander N" first="Neal D E" last="Alexander">Neal D E. Alexander</name>
<affiliation wicri:level="1"><nlm:affiliation>MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK neal.alexander@lshtm.ac.uk.</nlm:affiliation>
<country wicri:rule="url">Royaume-Uni</country>
<wicri:regionArea>MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT</wicri:regionArea>
<wicri:noRegion>WC1E 7HT</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25575555</idno>
<idno type="pmid">25575555</idno>
<idno type="doi">10.1093/trstmh/tru204</idno>
<idno type="wicri:Area/PubMed/Corpus">001097</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001097</idno>
<idno type="wicri:Area/PubMed/Curation">001097</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001097</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001097</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001097</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination.</title>
<author><name sortKey="Alexander, Neal D E" sort="Alexander, Neal D E" uniqKey="Alexander N" first="Neal D E" last="Alexander">Neal D E. Alexander</name>
<affiliation wicri:level="1"><nlm:affiliation>MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK neal.alexander@lshtm.ac.uk.</nlm:affiliation>
<country wicri:rule="url">Royaume-Uni</country>
<wicri:regionArea>MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT</wicri:regionArea>
<wicri:noRegion>WC1E 7HT</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title>
<idno type="eISSN">1878-3503</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Diethylcarbamazine (administration & dosage)</term>
<term>Disease Eradication</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Filaricides (administration & dosage)</term>
<term>Health Plan Implementation (organization & administration)</term>
<term>Humans</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Diéthylcarbamazine (administration et posologie)</term>
<term>Filaricides (administration et posologie)</term>
<term>Filariose lymphatique ()</term>
<term>Humains</term>
<term>Mise en oeuvre des programmes de santé (organisation et administration)</term>
<term>Éradication de maladie</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diethylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diéthylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Mise en oeuvre des programmes de santé</term>
</keywords>
<keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Health Plan Implementation</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Disease Eradication</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Filariose lymphatique</term>
<term>Humains</term>
<term>Éradication de maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lymphatic filariasis has been targeted for elimination by 2020, and a threshold of 65% coverage of mass drug administration (MDA) has been adopted by the Global Programme to Eliminate Lymphatic Filariasis (GPELF). A recent review by Babu and Babu of 36 studies of MDA for lymphatic filariasis in India found that coverage, defined as receipt of tablets, ranged from 48.8 to 98.8%, while compliance, defined as actual ingestion of tablets, was 22% lower on average. Moreover, the denominator for these coverage figures is the eligible, rather than total, population. By contrast, the 65% threshold, in the original modelling study, refers to ingestion of tablets in the total population. This corresponds to GPELF's use of 'epidemiological drug coverage' as a trigger for the Transmission Assessment Surveys (TAS), which indicate whether to proceed to post-MDA surveillance. The existence of less strict definitions of 'coverage' should not lead to premature TAS that could impair MDA's sustainability.</div>
</front>
</TEI>
</pubmed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006F15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 006F15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= PMC:4321021 |texte= Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25575555" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |